Total Funding
44
72
Total FundingPost-IPO Equity raised
Growth Score
-27 pts
Heat Score
22 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
21374
Shattuck Labs is a biotechnology company that provides novel class biologic medicines for the treatment of cancer and autoimmune disease.
- Taylor Schreiber: Chief Executive Officer & Co-founderPast Role: Pelican Therapeutics, Scientific Founder
- Josiah Hornblower: Founder & Executive Chairman
About the Company
Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC) platform, a novel class of dual-function fusion proteins with applications in oncology and autoimmune disease. The company’s lead program, SL-279252 (PD1-Fc-OX40L), is being studied in a Phase I trial in collaboration with Takeda
Pharmaceuticals.
Its technology focuses on immuno-oncology research targeted towards patients with many cancer types, including melanoma, lung, and bladder, by endowing one molecule with multiple functions, with applicability across the entire spectrum of human disease that enables medical researchers to find a quick and painless detection of malignancy for later-stage cancer patients.
